Investors NewsSearch: Jun 11, 2026Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results Jun 10, 2026Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C Apr 22, 2026Rafael Holdings Announces Patent Licensing Agreement with MIT for "Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease" Mar 16, 2026Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results Dec 11, 2025Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results Oct 29, 2025Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results Oct 28, 2025Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors Sep 16, 2025Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old Aug 27, 2025Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) Jun 18, 2025Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data 1 2 3 4 5 6 << < > >>
